Serendex CEO: Disappointing share price development
The large-scale IPO of biotech company Serendex has not been off to a flying start. The share price has plummeted since the IPO on July 11th, which has compelled the CEO to comment on the adverse development.
BY BENJAMIN WERNER CHRISTENSEN
The Danish biotech Serendex, which recently went public in Norway, has been off to a poor start to its life as a listed company – so poor, in fact, that management has found it necessary to make a public statement about the development.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
